A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This study is testing two different combinations of cancer treatments to see which one works better at shrinking melanoma that has spread to the brain. By comparing these treatments, doctors hope to find more effective ways to control the cancer and improve patient outcomes.

You may be eligible if you have melanoma that has spread to the brain and carries a specific genetic marker called the BRAF-V600 mutation. Participants must be able to undergo an MRI to track the cancer and should not have received previous whole-body treatment for metastatic melanoma.

Participants will be randomly assigned to receive one of two treatment groups, both of which involve medications that either block cancer growth or help your immune system fight the disease. You will have regular check-ups and brain scans throughout the study to monitor how your body responds to the treatment.

This study is currently recruiting patients at medical centers in Birmingham, Fairhope, and Mobile, Alabama. You should talk with your oncologist to see if this trial is the right fit for your personal medical history.